Low molecular weight Myc-max inhibitors

Details Low molecular weight Myc-max inhibitors Low molecular weight Myc-max inhibitors

2011-01-18

2011-01-18

Shameem, Golam M (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S184000, C546S192000, C546S209000, C548S146000, C548S182000, C548S183000, C514S315000, C514S365000, C514S369000

Reexamination Certificate

active

07872027

ABSTRACT:
Compounds and compositions for interfering with the association of Myc and Max are described herein. These compounds and compositions are useful in methods inhibiting growth or proliferation of a cell. Methods of inhibiting growth or proliferation of a cell are provided, comprising contacting the cell with an amount of a compound that interferes with Myc and Max association effective to inhibit growth or proliferation of the cell.

REFERENCES:
patent: 4552891 (1985-11-01), Ho et al.
patent: 5208250 (1993-05-01), Cetenko et al.
patent: 5362733 (1994-11-01), Backstrom et al.
patent: 5464856 (1995-11-01), Cetenko et al.
patent: 5889037 (1999-03-01), Backstrom et al.
patent: 6121303 (2000-09-01), Backstrom et al.
patent: 6673816 (2004-01-01), Esswein et al.
patent: 7026343 (2006-04-01), Prochownik et al.
Wang et al (2003): STN International HCAPLUS database, (Columbus, Ohio), Accession No. 2003:97274.
Cetenko et al (1990): STN International HCAPLUS database, (Columbus, Ohio), Accession No. 1990:235298.
Solow-Cordero et al (2004): STN International HCAPLUS database, (Columbus, Ohio), Accession No. 2004:703129.
Aamlid et al (1989): STN International HCAPLUS database, (Columbus, Ohio), Accession No. 1989:227493.
Hanefeld et al (1993): STN International HCAPLUS database, (Columbus, Ohio), Accession No. 1994:217393.
Bazarov AV et al. A modest reduction in c-myc expression has minimal effects on cell growth and apoptosis but dramatically reduces susceptibility to Ras and Raf transformation. Cancer Res. Feb. 1, 2001;61(3):1178-86.
Berg T, et al. Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embyro fibroblasts. Proc Natl Acad Sci U S A. Mar. 19, 2002;99(6):3830-5.
Brodeur GM. Molecular pathology of human neuroblastomas. Semin Diagn Pathol. May 1994;11(2):118-25.
Cutshall NS, O'Day C, Prezhdo M. Rhodanine derivatives as inhibitors of JSP-1. Bioorg Chem Med Lett. Jul. 2005;15(14) 3374-9.
Dang CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol. Jan. 1999;19(1):1-11.
Davis AC, et al. A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice. Genes Dev. Apr. 1993;7(4):671-82.
de Alboran IM et al. Analysis of C-MYC function in normal cells via conditional gene-targeted mutation. Immunity. Jan. 2001;14(1):45-55.
DuHadaway JB et al. Immunohistochemical analysis of Bin1/Amphiphysin II in human tissues: diverse sites of nuclear expression and losses in prostate cancer. J Cell Biochem. Feb. 15, 2003;88(3):635-42.
Eagle LR, Yin X, Brothman AR, Williams BJ, Atkin NB, Prochownik EV. Mutation of the MXI1 gene in prostate cancer. Nat Genet. Mar. 1995;9(3):249-55.
El Gedaily A et al. Discovery of new DNA amplification loci in prostate cancer by comparative genomic hybridization. Prostate. Feb. 15, 2001;46(3):184-90.
Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell. Aug. 1999;4(2):199-207.
Felsher DW. Reversibility of oncogene-induced cancer. Curr Opin Genet Dev. Feb. 2004;14(1):37-42.
Fieber W et al. Structure, function, and dynamics of the dimerization and DNA-binding domain of oncogenic transcription factor v-Myc. J Mol Biol. Apr. 13, 2001;307(5):1395-410.
Flores I, Murphy DJ, Swigart LB, Knies U, Evan GI. Defining the temporal requirements for Myc in the progression and maintenance of skin neoplasia. Oncogene. Aug. 5, 2004;23(35):5923-30.
Ge K et al. Losses of the tumor suppressor BIN1 in breast carcinoma are frequent andreflect deficits in programmed cell death capacity. Int J Cancer. Feb. 1, 2000;85(3):376-83.
Giorello L et al. Inhibition of cancer cell growth and c-Myc transcriptional activity by a c-Myc helix 1-type peptide fused to an internalization sequence. Cancer Res. Aug. 15, 1998;58(16):3654-9.
Gomez-Curet I, Perkins RS, Bennett R, Feidler KL, Dunn SP, Krueger LJ. c-Myc inhibition negatively impacts lymphoma growth. J Pediatr Surg. Jan. 2006;41(1):207-11.
Grandori C, Cowley SM, James LP, Eisenman RN. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol. 2000;16:653-99.
Huang MJ et al. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Exp Hematol. Nov. 2006;34(11):1480-9.
Husain M, Sarveshwar IS. Synthesis & biodynamic activities of 5-(substituted benzylidene)- . . . -4-oxothiazolidine-2-thiones. Ind J Chem. 1985;24B:761-4.
Incles CM, Schultes CM, Neidle S. Telomerase inhibitors in cancer therapy: current status and future directions. Curr Opin Investig Drugs. Jun. 2003;4(6):675-85.
Jain M, Arvanitis C, Chu K, Dewy W, Leonhardt E, Trinh M, Sundberg CD, Bishop JM, Felsher DW. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science. Jul. 5, 2002;297(5578):102-4.
Jenkins RB et al. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res. Feb. 1, 1997;57(3):524-31.
Jung KC et al. Fatty acids, inhibitors for the DNA binding of c-Myc/Max dimer, suppress proliferation and induce apoptosis of differentiated HL-60 human leukemia cell. Leukemia. Jan. 2006;20(1):122-7.
Kaltz-Wittmer C et al. FISH analysis of gene aberrations (MYC, CCND1, ERBB2, RB, and AR) in advanced prostatic carcinomas before and after androgen deprivation therapy. Lab Invest. Sep. 2000;80(9):1455-64.
Kamijo T et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell. Nov. 28, 1997;91(5):649-59.
Karlssson A et al. Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood. Apr. 1, 2003;101(7):2797-803.
Khodair AI. A convenient synthesis of 2-arylidene-5H-thiazolo[2,3-b]quinazoline-3,5[2H]-diones and their benzoquinazoline derivatives. J Hetercycl Chem 2002;39(6)1153-60.
Kiessling A, Sperl B, Hollis A, Eick D, Berg T. Selective inhibition of c-Myc/Max dimerization and DNA binding by small molecules. Chem Biol. Jul. 2006;13(7):745-51.
Kleine-Kohlbrecher D, Adhikary S, Eilers M. Mechanisms of transcriptional repression by Myc. Curr Top Microbiol Immunol. 2006;302:51-62.
Kolly C et al. Proliferation, cell cycle exit, and onset of terminal differentiation in cultured keratinocytes . . . J Invest Dermatol. May 2005;124(5):1014-25. Erratum in: J. Invest Dermatol. Dec. 2006;126(12):2734.
Kumagai T et al. Eradication of Myc-overexpressing small cell lung cancer cells transfected with herpes simplex virus thymidine kinase gene containing Myc-Max . . . Cancer Res. Jan. 15, 1996;56(2):354-8.
Leglise MC, Dent GA, Ayscue LH, Ross DW. Leukemic cell maturation: phenotypic variability and oncogene expression in HL60 cells. Blood Cells. 1988;13(3):319-37.
Leonetti C et al. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice. J. Natl Cancer Inst. Apr. 3, 1996;88(7):419-29.
Lipinski C, Hopkins A. Navigating chemical space for biology and medicine. Nature. Dec. 16, 2004;432(7019):855-61.
Mateyak MK, Obaya AJ, Adachi S, Sedivy JM. Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ. Oct. 1997;8(10):1039-48.
McGuffie EM, Catapano CV. Design of a novel triple helix-forming oligodeoxyribonucleotide directed to the major promoter of the c-myc gene. Nucleic Acids Res. Jun. 15, 2002;30(12):2701-9.
Mo H, Henriksson M. Identification of small molecules that induce apoptosis in a Myc-dependent manner and inhibit Myc-driven transformation. Proc Natl Acad Sci U S A. Apr. 18, 2006;103(16):6344-9.
Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene. May 13, 1999;18(19):3004-16.
Neumann CA et al. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature. Jul. 31, 2003;424(6948):561-5.
Nilsson JA et al. Targeting ornithine decarboxylase in Myc-induced lym

Affiliated with

Also associated with

Rating

Low molecular weight Myc-max inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Low molecular weight Myc-max inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Low molecular weight Myc-max inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2654174